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Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) 
disease, is the leading cause of death due to bacterial infection worldwide, claiming 
nearly two million lives each year. Often, the immune system cannot eradicate the 
bacteria and the disease progresses into a latent state characterized by the presence of 
granulomas, which are lesions formed in order to prevent bacterial dissemination. This 
state of infection can persist for years. Current research has shown that the utilization of 
host cholesterol by M. tuberculosis plays a crucial role in the tenacity of this organism 
during latent infection. Understanding the mechanisms of cholesterol acquisition and 
degradation could provide researchers with novel platforms for the strategic 
development of anti-mycobacterial drugs.  
In order to further understand the pathways employed by M. tuberculosis during 
cholesterol utilization, a series of fluorescently labeled cholesterol analogues were 
synthesized by tethering cholesterol chloroformate to 1,8-naphthalimide moieties via a 
carbamate linkage. The analogues and their 4-amino-1,8-naphthalimide precursors 
were found to be intensely fluorescent in nonpolar environments such as 
 	  
dichloromethane and liposomes comprised of POPC. Their in vitro effects were 
evaluated using the Mtb research model M. smegmatis. Bacterial growth curves were 
consistent with active incorporation and degradation of the fluorescently labeled 
cholesterol compounds, while inhibitory effects were observed for the unconjugated 
naphthalimide fluorophores. Current studies are focused on the isolation and 
identification of cholesterol/fluorophore metabolites to help elucidate the mechanism of 
uptake and decomposition of these compounds. Preliminary results of these metabolite 
experiments are discussed with relation to the observed effects on M. smegmatis 
growth.  
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INTRODUCTION 
 
1.1 Tuberculosis: Prevalence and Treatment 
It is estimated that more than one third of the population worldwide currently 
harbors Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) 
disease. The bacterium claims approximately 2 million lives each year.1 Those with 
compromised immune systems, such as individuals suffering from HIV/AIDS and the 
very young and elderly, are more likely to become infected with the pathogen. 
Additionally, the bacterium remains the leading cause of death in those infected with 
HIV/AIDS.1 This synergy with HIV and the emergence of multi- and extensively drug-
resistant strains of Mtb (MDR-TB and XDR-TB)2 have necessitated the need for new 
anti-mycobacterial drugs.  
 The increasing prevalence of tuberculosis can partially be ascribed to diminished 
commercial interest in development of novel TB therapies. The most recent addition to 
the arsenal of anti-mycobacterial drugs arrived more than 50 years ago with the creation 
of rifampin in 1963. Current treatments for tuberculosis involve multi-drug regimes 
whose foundations consist of isoniazid, rifampin, ethambutol, and pyrazinamide.2 This 
course of concurrent antibiotic usage typically lasts 6-9 months and often requires 
additional or replacement drugs. Unfortunately, even such lengthy therapies are 
beginning to fail as MDR and XDR strains of Mtb spread at an alarming rate.3 To create 
additional therapies, we need to better understand the intricate pathogenic properties 
that have enabled M. tuberculosis to become such a relentless infectious agent. 
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Mycobacterium tuberculosis is a human-specific pathogen that belongs to the 
group Actinobacteria. Species belonging to the Mycobacterium genus of this group 
possess an extremely complex cell wall that serves as a protective barrier, and 
functions to modulate the immune response of the host (Figure 1.1). This critical 
feature, combined with a relatively protracted doubling time and the presence of 
numerous atypical biochemical pathways, has contributed greatly to the success of Mtb 
as an intracellular pathogen.6    
 
 
       
Figure 1.1. The cell wall of Mycobacterium tuberculosis contains a unique lipid 
composition, which contributes to the organism’s virulence. Courtesy of Hicks, R. 
P., and Clark, T. D. 7 
 
1.2 Host-Pathogen Interactions 
Transmission of M. tuberculosis occurs when an infected host expels 
contaminated aerosol droplets, which is done through coughing, sneezing, or even 
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routine speaking. A new host then inhales these infectious droplets and the bacteria 
make their way to the alveoli. The host’s immune cells, specifically macrophages, then 
engulf the bacteria. This internalization is designed to destroy the invading body and is 
accomplished by the creation of a phagosome around the bacterium.8,9 Typically, the 
intraphagosomal compartment in which the bacterium resides is acidified to a pH of 5.0 
within 10-12 minutes. The foreign organism then begins to mix with lysosomal content, 
which has been shown to be associated with an increased level of hydrolytic activity and 
a brief period of superoxide generation.8 However, phagosomes containing Mtb do not 
experience the full drop in pH. Instead the intraphagosomal compartment maintains a 
pH of 6.4, allowing only minimal lysosomal fusion and proteolytic activity.8 During this 
time, the bacteria undergo rapid replication within the macrophage until an adaptive-
immune response is mounted. 
 A consequence of this adaptive-immune response is the formation of a stratified 
granuloma, which is the histological hallmark of tuberculosis infection.9 These 
granulomas, originally called tubercles, can vary in composition and are characterized 
as solid, caseous, or end-stage cavitary. Granulomas of the caseous and cavitary 
nature are distinguished by the presence of caseum, a cheese-like substance formed 
from liquefied tissue. If these tubercles expand into the bronchial passages, viable 
bacteria can be expelled into the environment causing transmission of the disease. 
However, the formation of caseous granulomas appears to be an unavoidable step 
towards bacterial containment.9 This stage of disease can result in a continued active 
bacterial infection, often leading to further host deterioration, or in successful restriction 
of the bacteria by the host immune system. The latter is characterized by the 
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encapsulation of the granuloma by a fibrous capsule, which prevents dissemination of 
M. tuberculosis and the presence of host symptoms.  
Despite the dedicated effort of the immune system to eradicate Mtb, a stable 
bacterial population continues to persist within the isolated environment of the 
granuloma. Increasing evidence10 indicates that this consistency in bacterial counts is 
the result of an equilibrium that is reached between replication and bacterial death, 
rather than establishment of a persistent colony of non-replicating bacteria. Although M. 
tuberculosis is able to derail maturation of the phagosome, the intracellular environment 
it occupies remains relatively hostile.8,9 
 
1.3 The Role of Host Lipids 
 Mtb manifests several unique adaptations to cope with these harsh conditions, 
modifying its cell wall and shifting its dominant metabolic state.11 Genome-wide 
microarray analyses of the Mtb transcriptome indicate that many of the same bacterial 
genes up-regulated during in vitro growth under unfavorable conditions (e.g., limited 
nutrients and oxidative stress), are also up-regulated during infection.12 Interestingly, a 
significant number of these up-regulated genes are involved in lipid metabolism. Other 
studies have shown decreased virulence in Mycobacterium strains containing mutations 
in these same regions,13-15 implying that lipid metabolism plays a significant role in 
pathogenesis. Furthermore, experiments have demonstrated that the primary cells 
infected with M. tuberculosis within the granuloma are foamy macrophages.16 Foamy 
macrophages are characterized by the increased formation of intracellular lipid droplets 
containing esterified cholesterol. It is believed that specific lipids found on the cell wall of 
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Mtb cause disruption in the normal lipid processing of these macrophages, which in turn 
provides the bacteria with a nearby food source. The importance of lipid metabolism 
during this stage of infection prompted significant research focused on the processing of 
host fatty acids, particularly cholesterol, by Mtb. This has led to an increased 
understanding of cholesterol transport and catabolism by M. tuberculosis, as well as its 
association with virulence. 
 
1.4 Cholesterol Import 
The M. tuberculosis genome contains the mce4 regulon, which encodes for an 
ATP-binding cassette-like transporter. The identity of this transport system’s substrate 
remained unclear until experiments with an Mtb relative, Rhodococcus jostii RHA1, 
showed diminished steroid uptake by mce4 mutants.17 The results indicated that wild-
type RHA1 was able to grow on cholesterol, 4-androstene-3,17-dione, 5-α-cholestanol, 
5-α-cholestonone, cholic acid, progesterone, and β-sitosterol. A mutant strain with the 
mce4 deletion maintains the ability to grow on 4-androstene-3,7-dione, cholic acid, and 
progesterone. However, it is unable to grow on the other compounds shown in Table 
1.1.  
 
Table 1.1. Growth of wild-type RHA1 and Δmce4 mutant on various steroids. 
 Wild-type Δmce4 
Cholesterol ✓ ✖ 
4-androstene-3,17-dione ✓ ✓ 
5-α-cholestanol ✓ ✖ 
5-α-cholestanone ✓ ✖ 
Cholic acid ✓ ✓ 
Progesterone ✓ ✓ 
β-sitosterol ✓ ✖ 
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These data indicate that the minimal substrates for the mce4 transport system 
are cholesterol, β-sitosterol, 5-α-cholestanol, and 5-α-cholestanone. However, this does 
not exclude the possibility that progesterone, cholic acid, and 4-androstene-3,7-dione 
are also recognized and transported,as a redundant transporter for these compounds 
could also be present. It is important to note the structural similarities of the confirmed 
mce4 substrates (Figure 1.2). Each substrate possesses a long lipophilic side chain, 
which may be a requirement for transport through this system.  
 
 
  
Figure 1.2. Substrates of the mce4 transport system.17 A) cholesterol B) 5-α-
cholestanol C) β-sitosterol D) 5-α-cholestanone. 
 
 Additional studies using M. tuberculosis concluded that deletion of the mce4 
operon nullified the bacteria’s inability to grow on cholesterol and inside of activated 
macrophages.18,19 Combined, these results indicate the cholesterol transport system 
encoded for by the mce4 operon plays an important role in M. tuberculosis virulence.  
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1.5 Cholesterol Catabolism  
A considerable amount of research has been carried out to decipher the complex 
series of enzymatic reactions used by M. tuberculosis to catabolize cholesterol. Many of 
these experiments involve the use of bacterial strains with putative steroid processing 
genes knocked out, in order to identify the metabolites formed thereby.20-22 Another 
method involves the expression and subsequent purification of recombinant enzymes 
followed by biochemical assays with the presumed substrate.2  
 Cholesterol catabolism is initiated at both the hydroxyl group located on the A 
ring of the steroid and at the terminal carbons on the lipophilic side chain2 (Figure 1.3). 
For easier understanding, these processes are often depicted as distinct and sequential 
pathways for ring degradation and side chain metabolism, though they can occur 
simultaneously in vivo.20  
 
 
 
Figure 1.3. Points of metabolic initiation on cholesterol. 
 
Metabolism of the steroid ring core begins with the oxidation of the A ring 
hydroxyl group followed by isomerization to an α,β-unsaturated ketone (Figure 1.1). 
This is followed by further desaturation of the A ring to yield a dienone product, and 
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subsequent hydroxylation of C9 on the adjacent ring.20 Interestingly, the addition of the 
hydroxyl group leads to the non-enzymatic aromatization of the A ring and opening of 
the B ring. Additional hydroxylation followed by meta-cleavage causes the aromatic A 
ring to open for continued degradation. An ensuing hydrolysis reaction results in two 
products, 2-hydroxy-hexa-2,4-dienoic acid (HHD) and DOHNNA. HHD is converted to 
pyruvate and propionate, but any further reactions of the C and D rings found in 
DOHNNA are poorly understood. Recently, it was shown that DOHNNA, sometimes 
referred to as HIP, is thioesterifed to coenzyme A, but the ultimate fate of this 
compound remains unknown.2  
 
 
 
Figure 1.4. Cholesterol ring degradation by M. tuberculosis. These metabolites 
were identified using gene knockout experiments, as well as biochemical assays 
with recombinant enzymes.2-3,13-14,20,23,25,46,51,52 
 
 
9 	  
M.tuberculosis is thought to catabolize the cholesterol side chain through a series 
of β-oxidation cycles. However, the vast number of β-oxidation genes present in the Mtb 
genome causes the functional assignment for individual steps in this pathway to 
become convoluted. Despite this genetic redundancy, several experiments have 
demonstrated the action of specific enzymes for individual metabolic steps or narrowed 
the possibilities for assignment by monitoring gene regulation during growth on certain 
carbon sources.19-22  
 Before β-oxidation can begin, the terminal carbon on the side chain must be 
completely oxidized to a carboxylic acid and then activated through thioesterification to 
coenzyme A (Figure 1.5). Complete conversion of the side chain requires three cycles 
of β-oxidation, each cycle including a series of desaturation, hydration, oxidation, and 
finally thiolysis.2 β-Oxidation of the side chain produces two units of propionyl-CoA and 
one unit of acetyl-CoA.23  
 The resulting C2 and C3 carbon units produced from cholesterol catabolism can 
be fed into additional metabolic and biosynthetic pathways. Acetyl-CoA units formed 
during this process can be converted to a useable energy source via the TCA cycle and 
glyoxylate shunt.2 Additionally, the propionyl-CoA so generated can either be converted 
into pyruvate and succinate through the methylcitrate cycle (MCC) or used in the 
biosynthesis of cell wall lipids. This latter pathway, termed the methylmalonyl pathway 
(MMP), is believed to have developed as a shunt for excess propionyl-CoA, as 
accumulation of this metabolite has been shown to be toxic to M. tuberculosis.24 Studies 
using mass spectroscopy have provided data supporting this incorporation into cell wall 
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lipids, particularly those linked with Mtb virulence, such as sulfolipid (SL-1)25 and 
phthiocerol dimycocerosates (PDIM).26 
 
 
 
 
Figure 1.5. Cholesterol side chain degradation by M. tuberculosis. 2-3,13-
14,20,23,25,46,51,52 
 
 
Tremendous advances have been made in the understanding of how M. 
tuberculosis utilizes host cholesterol during infection. However, many questions remain 
unanswered and further exploration is needed to shed light on this critical pathway used 
by M. tuberculosis, as it may provide researchers with novel targets for future anti-
mycobacterial drugs. The following chapters will describe efforts to further elucidate 
modes of cholesterol transport and processing in Mycobacterium spp., using 
fluorescently-labeled analogues of cholesterol.  
 
 
 
 
	   
 
2. SYNTHESIS AND PROPERTIES OF NAPHTHALIMIDE DERIVATIVES 
AND THEIR CHOLESTEROL CONJUGATES 
 
2.1 Naphthalimide Properties and Biological Relevance 
There is a significant body of literature that describes the labeling of the A- and 
D-rings of cholesterol with fluorophores.31,32 For the reasons described below, 4-
aminonaphthalimides were chosen to label our 
cholesterol probe compounds. Naphthalimide 
derivatives exhibit an array of biological activities, 
including antibacterial and anticancer properties.33 
Their large π-conjugated backbone enables 
potential interactions with a diverse set of biological 
targets through π-π stacking and other non-covalent 
forces. One such target is DNA gyrase, which is responsible for the relaxation of 
supercoiled DNA in bacteria and whose inhibition would ultimately prevent cell 
replication.33 These molecules posses a cyclic imide group, and with appropriate choice 
of group “R” can be both hydrophobic and neutral, thus allowing for their transport 
across biological membranes. This advantageous feature, along with the fluorescent 
properties possessed by 4-substituted naphthalimides, has piqued the interest of 
researchers as the compounds could be exploited in cellular probes. Indeed, an NH2 
group at position 4 of the aromatic system was expected to serve as a nucleophilic site 
for attachment to steroids.  
R
N OO
NH2
1!
2!
3!4!5!
7!
6!
8!
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2.2 Synthesis of N-Alkyl-1,8-Naphthalimide Derivatives 
The typical synthetic routes to N-alkyl-1,8-napthalimide derivatives include the 
alkylation of 1,8-naphthalimide potassium salts with alkyl halides or the reaction of 1,8-
naphthalic anhydride with a primary amine under reflux conditions (Scheme 2.1A). The 
use of the Mitsunobu reaction (Scheme 2.1B) and the interaction between 1,8-
naphthalic anhydride and an aryl azide with iodomethylsilane have also shown 
success34 (Scheme 2.1C).  
 
Scheme 2.1  
 
 
O OO
OH
O
NHR
O
O
R
NO
-H2O!
RNH2!
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O
H
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ROH!
O
R
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R
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CH3CN, rt!
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13 	  
However, the product yields of these reactions have been shown to be moderate 
at best when the naphthalimide ring is substituted with an electron-withdrawing group, 
such as a nitro group.34 This limited their usefulness for our synthetic purposes, as a 4-
nitro substituent is the most logical precursor to the desired 4-amino group. Therefore, 
the sonochemical method developed by Triboni et al.34 was employed to synthesize a 
series of known N-substituted 4-nitro-1,8-naphthalimides. This mode of synthesis 
displays high regioselectivity and resulting imide products are obtained in good yields. 
The starting material, 4-nitro-1,8-naphthalic anhydride (3.08 mmol), was 
suspended in 150 mL of deionized water within a 250 mL Erlenmeyer flask. A 6.75-fold 
excess of a primary amine, either N-butylamine, 3-methoxypropylamine, or 3-amino-1-
propanol, was added to the suspension and gently swirled until evenly distributed. The 
flask was then placed in a sonication bath, submerging the suspension (Scheme 2.2). 
During the course of the reaction, the flask was removed at 30-minute intervals and 
gently swirled to remove any solid that had collected on the flask wall. After 90 minutes, 
the suspension adopted an iridescent appearance. The solid was isolated using vacuum 
filtration and collected on a fine glass frit. Once separated, the solid was transferred 
from the frit to a tared round-bottom flask and placed on a vacuum line to finish drying. 
The resulting N-butyl imide was obtained in yields >95%, while the methoxypropyl and 
hydroxypropyl analogues were isolated in yields of 71 and 46%, respectively. The 
discrepancies observed between product yields likely arise from the greater water-
solubility exhibited by the more hydrophilic head groups.  
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Scheme 2.2 
 
 
The first method employed to reduce the aromatic nitro group on the isolated 
imide product involved its suspension in propanol followed by the addition of activated 
zinc and formic acid35 (Scheme 2.3). The reaction was allowed to stir under nitrogen for 
24 hours. After which, the solution was cooled to room temperature, diluted with CH2Cl2, 
and washed twice with deionized water in a separatory funnel. The organic phase was 
dried over Na2SO4 and filtered through fluted filter paper to remove any solids. The 
remaining solvent was removed under vacuum leaving a red-orange solid in 73% yield. 
While this method was successful in reducing the nitro group in decent yields, complete 
removal of zinc salts proved to be laborious and the use of a hydrogenation apparatus 
was pursued instead. 
 
 
 
 
O OO
NO2
H2O!
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R-NH2!
N OO
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R
N OO
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R
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Scheme 2.3 
 
 
To carry out the reduction using a hydrogenator, palladium on carbon catalyst (1 
mg per 10 mg of naphthalimide) was placed into a Pyrex bottle and immediately 
followed by 150 mL of 95% ethanol. The previously synthesized N-alkyl 4-nitro-1,8-
naphthalimide was then added to the solution as a dry solid.36 The bottle was placed on 
the hydrogenator and allowed to react for 90 minutes under 34 PSI of H2 (Scheme 2.2). 
When complete, the dark green solution was filtered through fluted filter paper into a 
tared round-bottom flask. The ethanol was removed under vacuum leaving the reduced 
naphthalimide in yields of ~95%. 
Following the successful reduction of the 4-nitro naphthalimides, strategies for 
their covalent attachment to cholesterol analogues were explored. Direct SN2 attack of 
the 4-amino group on a secondary alkyl halide, such as cholesteryl chloride, seemed 
unlikely to succeed as aromatic amines typically display poor nucleophilicity. 
Consequently, we turned to cholesteryl chloroformate, a commercially available 
compound that possesses a highly electrophilic carbonyl group.  
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Scheme 2.4 
 
 
Attachment of the reduced naphthalimide to cholesterol chloroformate was first 
attempted in THF. Both compounds were added to the stirring solvent along with 
triethylamine and allowed to react at room temperature for several days. This method 
was later replaced by suspending the reduced naphthalimide (0.18 mmol) in 8 mL of 
ethyl acetate under nitrogen and then placing the flask into an oil bath that had been 
heated to 55°C (Scheme 2.4). Once heated, a slight excess (0.20 mmol) of 
diisopropylethylamine (DIPEA) was added in one portion and allowed to stir for 5 
minutes. Cholesterol chloroformate was added to the flask in slight excess (0.28 mmol) 
and the resulting orange suspension was allowed to react for several days. Reaction 
progress was monitored by TLC and showed a relatively fast blue spot, compared to the 
starting naphthalimide, which grew in intensity over time. On day 5, the solution was 
cooled to room temperature and the formation of a yellow precipitate was observed. The 
solution was concentrated by removing the volatiles under vacuum and the resulting 
gold solid was suspended in a small amount of CH2Cl2. The desired product was 
isolated using flash column chromatography. A mixture of hexane and CH2Cl2 (1:1) was 
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used to remove any unreacted cholesterol chloroformate and the remaining mixture was 
separated using CH2Cl2 and methanol (20:1). A fast-moving intensely blue fluorescent 
material was collected and the solvent was removed under vacuum yielding a lemon-
yellow solid, which was dried under high vacuum. Product structures were confirmed 
using NMR and mass spectroscopy (Figure 2.1). 
These conditions provided better yields for both the butyl and methoxypropyl 
compounds than previous attempts. However, the alcohol group on the propanol 
naphthalimide proved to be a better nucleophile compared to the aromatic amine and 
thus yielded an “inverted” version of our desired compound (Scheme 2.5). This 
rearrangement prevented the inclusion of this compound in the subsequent 
fluorescence and biological studies.  
 
Scheme 2.5 
 
 
 
 
 
 
DIPEA!
EtOAc!
42°C!
cholesteryl!
 chloroformate!N OO
NH2
HO
ON
H2N
O
O
O
O
18 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1. Proton NMR of Compound 2B in CDCl3. The carbamate NH resonance, 
indicative of fluorophore attachment, appears at 7.53 ppm.  
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2.3 Spectroscopic Properties of Compounds 1-2 
Absorption and emission spectra were obtained for compounds 1-2 (Figure 2.2) 
in milieu of varying polarities, including dichloromethane (CH2Cl2), sodium phosphate 
buffer, and mammalian-modeled liposomes. In CH2Cl2, both compounds 1A and 1B 
exhibited maximum absorption at 405 nm, while compounds 2A and 2B showed 
maximum absorption at 373 and 371 nm, respectively. When excited at their 
absorbance maxima, the free naphthalimide fluorophores (compounds 1A and 1B) 
emitted green light in a single, broad featureless band with greatest intensity at 482 nm. 
Their cholesterol counterparts showed maximum emission of 443 nm (compound 2A) 
and 441 nm (compound 2B). These data complements the difference in color observed 
when compound solutions are visually observed using a handheld long wavelength 
lamp. 
 
 
Figure 2.2. Fluorescent probes used in this study. 
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All four of the fluorophores demonstrated negative solvatochromatic behavior as 
each of their absorption and emission spectra featured hypsochromic shifts when 
suspended in sodium phosphate buffer compared to CH2Cl2 (Tables 2.1 and 2.2). This 
characteristic trait can be utilized to derive the probable location of the fluorophore when 
both non-polar and polar environments are present, as is the case with liposomes 
suspended in aqueous buffer solution.  
 
Table 2.1. Photophysical properties of fluorescent probes. 
 
Compound Abs. λmax CH2Cl2 Abs. λmax Buffer Δλ 
1A 405 nm 432 nm -27 
2A 373 nm 387 nm -14 
1B 405 nm 430 nm -25 
2B 371 nm 378 nm -7 
 
 
Table 2.2 
 
Compound Em. λmax CH2Cl2 Em. λmax Buffer Δλ 
1A 482 nm 540 nm -58 
2A 443 nm (ϕf = 0.70) 485 nm -42 
1B 482 nm 540 nm -58 
2B 441 nm (ϕf = 0.70) 487 nm -46 
 
To explore how each of the free and cholesterol-tethered fluorophores might 
interact with cell membranes, the spectroscopic properties of the individual compounds 
were assessed in liposomes. Liposomes are small vesicles consisting of a lipid bilayer 
that are used as rudimentary model systems for cell membranes, which are significantly 
more complex.37 The liposomes used in these assays were composed of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and cholesterol, which are lipids known to 
be located in mammalian cell membranes.  
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Liposomes were prepared using a 7:3 ratio of POPC to cholesterol in sodium 
phosphate buffer (0.0993 M). POPC (22.8 mg) and 5.03 mg of cholesterol were placed 
into a tared round bottom flask and dissolved in a 50/50 mixture of CH2Cl2 and 
cyclohexane by gently swirling the solution. Once fully dissolved, the solvents were 
removed under vacuum and the remaining lipid film was dried on a high vacuum 
manifold for an hour. The dried lipids were hydrated by adding 15 mL of 0.0993 M 
sodium phosphate buffer to the flask, vortexing the solution for 5 minutes and then 
magnetically stirring the solution for 1 hour. The final lipid concentration equaled 2.0x10-
3 M. To obtain unilamellar vesicles, the solution was then placed in a plastic conical tube 
and subjected to 3 freeze-thaw cycles using liquid nitrogen to thoroughly freeze the 
solution and a lukewarm water bath to thaw the frozen mixture completely. Once the 
freeze-thaw cycles were completed, 1 mL aliquots of the thawed solution were extruded 
through a 0.1 µm polycarbonate membrane on a mini-extruder. In order to attain 
liposomes of uniform size, the solution was passed through the filter 15 times. The 
extruded solution was translucent and had adopted a faint blue color compared to the 
pre-extruded solution. 
After preparation, 3 mL of the extruded liposome solution was added to a quartz 
cuvette along with a small stir bar. The solution was allowed to gently stir and a baseline 
fluorescence spectrum was obtained. To simplify the introduction of individual 
fluorophores to a liposome solution, compounds 1-2 were suspended in DMSO 
(7.31x10-3 M) to make a stock solution and then added to the cuvette using a syringe. 
Once added, a fluorescence spectrum was immediately acquired. Emission scans were 
taken at 5-minute intervals until 30 minutes had elapsed to monitor the rate of 
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fluorophore incorporation into the liposome bilayer and ensure sufficient time for 
association.  
 
Table 2.3. Integrated emission intensities in POPC liposomes. 
Time (minutes) Peak Area (2A) Peak Area (1A) Peak Area (1B) 
0 1.47974 e007 5.69047 e007 4.39031 e007 
5 1.47566 e007 5.53235 e007 4.19272 e007 
10 1.49729 e007 5.48989 e007 4.14062 e007 
15 1.52011 e007 5.47897 e007 4.10453 e007 
20 1.52419 e007 5.46936 e007 4.07436 e007 
25 1.52021 e007 5.45851 e007 4.06558 e007 
30 1.5366 e007 5.46565 e007 4.06148 e007 
 
The fluorescence intensity of both the free and cholesterol-bound fluorophores 
only showed slight fluctuations during the 30-minute time period (Table 2.3). Therefore, 
it is likely the compounds incorporate into the bilayer almost immediately after 
introduction into the cuvette. The addition of 1,6-diphenyl-1,3,5-hexatriene (DPH) 
solution to the cuvette containing the fluorophore-supplemented liposomes was used as 
a control to ensure the liposomes had remained intact throughout the assay. Inclusion 
of the fluorophores into the bilayer did not appear to have a substantial effect on 
liposome stability as the emission spectra obtained were characteristic of DPH 
incorporation into a non-polar environment. 
Although the fluorescence intensities showed little variation over time within the 
liposome solutions, there was a notable difference in emission maxima between 
compounds 2A and 2B. When suspended in either CH2Cl2 or buffer, the cholesterol 
conjugates emitted with greatest intensity at nearly identical wavelengths. However, 
when located in the liposome solution, compounds 2A and 2B displayed different 
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emission maxima values (Table 2.4). In light of the negative solvatochromatic behavior 
that characterizes these compounds, it is speculated that this incongruence may 
indicate the two compounds are oriented differently within the liposome and thus 
exposed to environments of different polarity. 
 
Table 2.4. Emission maxima of fluorescent probes in media of varying polarities. 
Compound Em. λmax CH2Cl2 Em. λmax Buffer Em. λmax Liposomes 
1A 482 nm 540 nm 508 nm 
2A 443 nm 485 nm 441 nm 
1B 482 nm 540 nm 518 nm 
2B 441 nm 487 nm 488 nm 
 
 When compared to the previously obtained emission spectra of compound 2A in 
both CH2Cl2 and buffer, the maximum observed in the liposome solution was similar to 
that of the compound in CH2Cl2 (Figure 2.3). In contrast, compound 2B showed an 
emission maximum at a wavelength similar to when it is enveloped in a buffer solution 
(Figure 2.4). The significant difference in the emission maxima seemed unusual 
considering the relatively small difference in the fluorophore structure, specifically a 
single oxygen atom incorporated into the naphthalimide head group (Figure 2.1). 
However, this group allows for electrostatic interactions and acts as a hydrogen bond 
acceptor, both behaviors that the butyl head group does not display.  
 
 
 
 
 
24 	  
 
 
Figure 2.3. Emission spectra of compound 2A in various solvent systems (Em. 
λmax CH2Cl2 = 443 nm, Em. λmax Buffer = 485 nm, Em. λmax Liposomes = 441 nm).  
 
 
 
Figure 2.4. Emission spectra of compound 2B in various solvent systems (Em. 
λmax CH2Cl2 = 441 nm, Em. λmax Buffer = 487 nm, Em. λmax Liposomes = 488 nm).  
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To better establish the location of compounds 2A and 2B within the bilayer, the 
emission spectra of each was compared to that of another cholesterol analogue 
previously synthesized (Figure 2.5). This compound contains a polyethylene glycol 
(PEG) group affixed to the imide N atom. The addition of a PEG group interferes with a 
molecule’s ability to cross biological membranes.38 Therefore, the PEGylated 
cholesterol conjugate acted as a control molecule whose location within the membrane 
would be limited relative to 2A and 2B.  
 
 
Figure 2.5. PEGylated fluorescent probe. 
 
 The PEGylated compound displays an emission maximum at 489 nm when 
suspended in a POPC liposome solution. Upon comparison of the emission maxima of 
compounds 2A and 2B, it was seen that the PEGylated conjugate exhibits an emission 
maximum nearly identical to that of 2B. However, the more lipophilic compound 2A 
shows a maximum nearly 45 nm away from those expressed by the others (Figure 2.6).  
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Figure 2.6. Emission spectra of compounds 2A, 2B and the PEGylated Control in 
POPC Liposomes (2A Em. λmax  = 441 nm, 2B Em. λmax = 488 nm, PEGylated 
compound Em. λmax = 489 nm).   
 
 
These results suggest that the PEGylated compound and compound 2B are 
experiencing relatively similar external environments compared to compound 2A. The 
presence of hydrogen bond acceptors in the head groups of both the PEGylated 
compound and 2B could cause the fluorescent portion to interact with the extracellular 
aqueous environment to a greater degree than the butyl head group does in compound 
2A. However, the increased noise displayed in the PEGylated spectrum compared to 
the 2B spectrum may indicate a more extensive association with the external aqueous 
environment (Figure 2.7). This difference could be explained by the PEGylated 
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compound’s increased capacity for H bonding, as it is capable of accepting 6 bonds 
whereas compound 2B can only accept 2 bonds.  
It is possible that the greater hydrophobicity displayed by compound 2A could 
cause the butyl head group to embed itself into the lipophilic cell membrane in a hairpin-
like arrangement (Figure 2.8). This change in external environment, however slight, 
could account for the larger difference in emission maximum observed for this 
cholesterol analogue compared to the other fluorescently labeled cholesterol 
compounds tested.  
 
 
Figure 2.7. Possible membrane orientations for compounds 2A, 2B and the 
PEGylated control within POPC liposomes. A) Proposed hairpin conformation for 
compound 2A. B) Proposed head group-associated conformation of 2B. C) 
Proposed extended conformation of the PEGylated compound.  
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Figure 2.8. Hairpin conformation of compound 2A. 
 
Paul and Guchhait determined the location of a lipophilic fluorophore probe within 
DMPC and DMPG liposomes.39 Their results indicated that the fluorophore was likely 
sequestered in the hydrophobic center of the lipid membrane as changing the lipid head 
group from choline to glycerol did not affect the fluorescence. Similarly, compound 2A 
was incorporated into POPE/POPG (3:1) liposomes and a fluorescence spectrum was 
obtained. The compound displayed an emission maximum at 481 nm within this set of 
liposomes, in contrast to the emission maximum at 441 nm seen in POPC liposomes 
(Figure 2.9).  This difference in emission maxima between liposome sets suggests that 
compound 2A is likely positioned near the polar head groups instead of the hydrophobic 
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tail region of the membrane.39 The similar emission maxima observed for compound 2A 
in POPC liposomes and CH2Cl2 could be due to the three methyl groups present on the 
choline group, which provide a more hydrophobic environment compared to 
ethanolamine and glycerol (Figures 2.10 and 2.11).  
 
 
 
 
Figure 2.9. Emission spectra for compound 2A in POPC and POPG/POPE 
liposomes (Em. λmax POPC = 441 nm, Em. λmax POPG/POPE = 481 nm). 
 
 
Taken together, the results obtained confirm that cholesterol A-ring modification 
does not preclude membrane uptake within model cell systems, and it was decided to 
test their biological effects on Mycobacterium. These experiments are described in the 
following chapter. 
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Figure 2.10. Possible conformations of compound 2A within POPC and 
POPG/POPE liposomes. The presence of hydrogen bond donor groups in B may 
favor the head group-associated conformation for compound 2A. 
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Figure 2.11. Lipid head groups present in the liposomes used in the described 
fluorescence experiments. 
	   
3. BIOLOGICAL ACTIVITY OF 1,8-NAPHTHALIMIDE CHOLESTEROL DERIVATIVES  
 
3.1 The Role of Mycobacterium smegmatis in Cholesterol Utilization Assays 
 The evidence for membrane incorporation of compounds 2A and 2B from the 
previously described liposome experiments prompted the decision to test the biological 
activity of our compounds within a live system. For these viability studies, the 
nonpathogenic research model organism Mycobacterium smegmatis was used. The 
bacteria possess approximately 70% of the same genes as their close relative M. 
tuberculosis, including genes involved in the transport of steroids and their subsequent 
degradation.40-42 Despite their similarities, the replication time of the two species differs 
greatly. The doubling time of M. smegmatis is roughly 3 hours, whereas M. tuberculosis 
usually takes 24 hours to replicate.43 The similar metabolic capabilities and reduced 
doubling time, as well as significantly decreased virulence, made M. smegmatis a 
suitable model organism for these assays.  
 
3.2 Susceptibility of M. smegmatis to Compounds 1-2 
 A disk diffusion assay was employed to determine the sensitivity of M. 
smegmatis to compounds 1-2 (Figure 3.1). The advantages of this technique include 
low cost and relative ease of interpretation.44 To perform this test, a sterile paper disk 
containing an aliquot of compound solution is placed in the center of a previously 
inoculated agar plate.44 The compound then radially diffuses out from the disk, creating 
a concentration gradient within the agar. If the bacteria are susceptible to the drug, they 
will fail to form colonies in areas where the appropriate concentration of compound is 
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present for inhibition. Growth covering the plate indicates the bacteria are resistant to 
the effects of the drug being tested.44  
 
 
Figure 3.1. Fluorescent probes used in bacterial assays. 
 
LB agar plates were prepared and an isolated colony of M. smegmatis was 
suspended in sterile PBS solution. LB agar plates were inoculated with the bacterial 
solution. A sterile paper disk was placed in the center of each inoculated plate and then 
test compounds were introduced onto the disks as solutions in DMSO (10 µL; stock 
concentration = 7.31x10-3 M). Plates were incubated for 3 days and then evaluated for 
bacterial sensitivity. No significant areas devoid of bacterial growth were observed, 
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indicating that under these conditions, M. smegmatis is not inhibited by compounds 1-2 
(Figure 3.2).  
 
 
 
Figure 3.2. Disk diffusion assay results for compounds 1A (A) and 1B (B). Neither 
disk showed significant bacterial inhibition. Note the small diffusion radius for the 
cholesterol-conjugated probe in B compared to the unconjugated naphthalimide in 
A.       
 
To detect bacterial uptake of the compounds tested, as well as any structural 
modification, the plates were examined under a UV light (xx nm). Particular alterations 
to the chromophore of compounds 1-2 could cause changes in the fluorescence 
observed. One such change is the acylation of the aromatic amine in compounds 1A 
and 1B, which a model reaction in our laboratory (Scheme 3.1) has shown to cause the 
green fluorescence normally exhibited by the compounds to shift to blue. Conversely, 
cleavage of the carbamate linkage could cause cells stained by conjugates 2A and 2B 
to appear fluorescent green as opposed to their usual blue (Scheme 3.2). While the 
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bacterial colonies appeared to fluoresce, implying compound uptake, no visible change 
in color indicative of modification was observed.  
 
Scheme 3.1 
 
 
Scheme 3.2 
 
 
Additionally, it was noted that the free naphthalimides 1A and 1B showed 
moderate diffusion into the media while their cholesterol conjugates, compounds 2A 
and 2B, remained either on the disk or in the immediate surrounding area (Figure 3.2). 
The difference in compound distribution can likely be attributed to the high 
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hydrophobicity displayed by the cholesterol analogues. In light of this finding, it was 
decided to use a liquid culture assay to reevaluate the effects of compounds 1-2 on M. 
smegmatis.  
 
3.3 Growth of M. smegmatis in the Presence of Compounds 1-2 
To better assess the impact of 1-2 on the growth of M. smegmatis, the bacteria 
were grown in liquid cultures supplemented with an individual probe molecule. 
Compounds 1-2 were introduced into cultures as emulsions in a nonionic surfactant, 
Tween-80 (2.5 mM). The addition of Tween-80 to culture media was done to circumvent 
the low solubility of the highly hydrophobic cholesterol conjugates in the media, as well 
as to reduce the extent of bacterial clumping that is typically seen in Mycobacterium 
cultures.45 
For this assay, M. smegmatis was grown in both nutrient-rich and minimal media 
to determine if the presence of additional carbon sources would have an effect on the 
utilization of compounds 1-2. It was hypothesized that the presence of our compounds 
would have a more significant impact on the cultures grown in minimal media, as the 
lack of alternative nutrients would likely place pressure on the organisms to derive its 
energy and carbon exclusively from the probe molecules. This pressure to use any 
accessible carbon sources is not unlike the intracellular environment where the 
pathogenic relative of M. smegmatis, M. tuberculosis, resides during infection.20 To 
monitor the growth of bacteria in both culture conditions, serial 10-fold dilutions were 
plated over a time period of one week. This method of growth assessment is more 
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accurate than OD600 measurements as it only accounts for viable cells, whereas the 
latter method includes both living and nonliving cells.  
For the assessment of compound effects in a nutrient-rich environment, a series 
of flasks containing sterile LB medium were prepared. An aliquot of Tween-probe 
emulsion was added to each flask, which was gently swirled until evenly distribution was 
achieved. Once the media were uniform, each culture was inoculated with a solution of 
M. smegmatis. This process was repeated using M9 media to evaluate the effects of 
compounds 1-2 in a nutrient-deprived environment. Each culture was then subjected to 
a series of serial dilutions and plated to obtain an initial CFU count. The flasks were 
placed in a shaker at 37°C and growth was monitored by plating serial 10-fold dilutions 
at 8-hour intervals until 48 hours had passed, then every 24 hours thereafter. The assay 
was discontinued once the cultures had been incubating for 168 hours. Colonies were 
counted two days after being plated. 
Results obtained from the LB cultures showed robust (exponential) growth for 
bacteria grown in compounds 1-2, as well as those grown in media supplemented with 
cholesterol (Figure 3.3), during the first 48 hours. After this, all cultures entered 
stationary phase, where viable counts slightly declined until the end of the assay.  
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Figure 3.3. Growth of M. smegmatis in LB medium supplemented with 
compounds 1-2 and Tween-80. Exponential growth the bacteria occurred within 
the first 48 hours. No statistically significant differences in growth were observed 
among the culture conditions tested. 
 
Curiously, the cultures grown in M9 medium demonstrated a similar growth 
pattern to that seen in the nutrient-rich cultures (Figure 3.4). The only notable exception 
between the two culture sets is the presence of a sharp transition point into stationary 
phase and slight decrease in viability seen in the LB series, but not in the M9 set.  
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Figure 3.4. Growth of M. smegmatis in M9 medium supplemented with 
compounds 1-2 and Tween-80. A less distinct stationary phase transition was 
observed compared to the growth curves for the LB media cultures shown in 
Figure 3.3.  
 
The assay was repeated to ensure reproducibility, and the same curve shapes 
were observed for both culture conditions. A subsequent literature search yielded 
evidence that Mycobacterium are capable of utilizing Tween-80 as a carbon source.46 
The abundance of Tween-80 (2% v/v) present in each culture was the assumed cause 
of the homogeneity observed in the growth curves for this assay. Tween-80 was omitted 
in all later growth studies and replaced with Tyloxapol, a detergent that has been shown 
to not have an effect on the viability and proliferation of Mycobacterium.47  
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3.4 Growth of M. smegmatis in the Presence of Compounds 1-2 within Minimal 
Media 
Multiple changes were made to the original method of growth assessment of M. 
smegmatis in the presence of compounds 1-2. In addition to the exchange of Tween-80 
for Tyloxapol (Figure 3.5), the bacteria were grown in 7H9 medium until mid-
exponential phase had been reached. When the OD600 value of the 7H9 culture had 
risen to ≈ 0.5, the bacteria were transferred into a defined minimal medium utilized by 
Pandey and Sassetti.47 The compounds of interest were introduced as Tyloxapol-
ethanol suspensions (1.15 mM).  
 
 
 
 
 
Figure 3.5. Detergents utilized for growth assays. A) Tween-80 B) Tyloxapol.  
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To prepare the initial culture, sterile 7H9 medium was added to a flask and then 
inoculated with a previously prepared bacterial suspension. Bacterial growth was 
monitored using OD600 measurements. Once mid-exponential phase had been reached, 
the 7H9 culture was divided into sterilized centrifuge tubes. The cells were pelleted by 
spinning at 10K rpm for 15 min and the supernatant was removed. The remaining 
bacterial pellet was washed with sterile PBS then centrifuged once more. This process 
was repeated. The solid residue in each tube was suspended in defined minimal 
medium. A fluorophore or conjugate solution was then added, and each tube was 
vortexed to evenly distribute both the compound and the bacteria. The culture within 
each centrifuge tube was then divided into equal aliquots among culture tubes for future 
CFU counts and metabolite identification studies, which will be discussed later in further 
detail. To assess the effects of compounds 1-2 on the growth of M. smegmatis, the 
process of plating 10-fold serial dilutions done for the Tween-80 assay was repeated. 
This procedure was performed every 24 hours for each compound/culture tube until one 
week had passed. This assay was done in triplicate.  
The results obtained from this modified method showed considerable differences 
in cell viability among the culture samples tested. Most notably is the enhanced growth 
of M. smegmatis grown in the presence of compounds 2A and 2B when compared to 
the control and cholesterol cultures (Figure 3.6). Furthermore, the free fluorophores, 
compounds 1A and 1B, showed an inhibitory effect when plotted against the other four 
samples.  
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Figure 3.6. Growth of M. smegmatis in defined minimal medium supplemented 
with compounds 1-2 and Tyloxapol. Cholesterol conjugates 2A and 2B showed 
enhanced growth compared to other compounds tested, as well as the control, 
which was supplemented with only Tyloxapol. P values ≤ 0.01 were deemed 
significant as assessed by the student’s 2-tailed T-test. Significant differences: 
Compound 1A = 48, 72 and 96 H. Compound 2A = 48, 96 and 144 H. Compound 1B 
= 24, 72 and 168 H. Compound 2B = 48 and 120 H. 
  
The emergence of distinct growth patterns during this assay could be attributed 
to the lack of alternative nutrients, such as Tween-80, provided by the media used in 
previous experiments. To shed light on the cause of the apparent preference of 2A and 
2B over natural cholesterol, as well as the hindering effects of 1A and 1B on M. 
smegmatis viability, focus was shifted to the isolation and identification of metabolites 
generated during these culture conditions. The results collected from the 
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aforementioned growth assays, as well as their implications for M. tuberculosis 
treatment, will be further examined in combination with the data obtained from these 
metabolite experiments in a later section.   
 
3.5 Extraction and Mass-Spectral Identification of Cholesterol- and Fluorophore-
Derived Bacterial Metabolites 
Analysis of metabolites from culture samples was conducted to gather further 
support for bacterial utilization of compounds 1-2 and to aid in the elucidation of their 
metabolism. The compounds targeted during these assays can be divided into three 
groups: unaltered compounds 1-2, known metabolites of cholesterol degradation by 
Mycobacterium, and a series of hypothetical metabolites derived from compounds 1-2.  
The collection of speculative metabolites from 2A and 2B was created using the 
reported pathway of cholesterol catabolism20 as a guide. Among this group, we were 
particularly interested to determine if fluorophore-labeled compounds analogous to the 
cholesterol metabolite 4-androstene-3,17-dione (AD) are formed (Figure 3.7). 
 
 
 
Figure 3.7. 4-Androstene-3,17-Dione (AD). 
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O
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 Production of this specific metabolite would indicate complete degradation of the 
cholesterol side chain accompanied by an inability to process the A-ring of the steroid. 
The prevention of ring degradation would likely be caused by the presence of the 
carbamate linkage that replaces the hydroxyl group on natural cholesterol. Preventing 
steroid ring metabolism could lead to an imbalance of propionyl-CoA and acetyl-CoA, 
which has been shown to have toxic effect on Mycobacterium.23,24  
Once the target compound list was made, databases containing the calculated 
mass-to-charge (m/z) ratios were generated in Excel (Appendix B). These databases 
were later used to assist in the identification of significant signals found in the mass 
spectra of the tested culture samples.  
Similar experiments have been conducted for the isolation and identification of 
specific cholesterol metabolites,20 as well as for Mycobacterial cell wall lipids 
components,48-50 which have been shown to play a pivotal role in the pathogen’s 
virulence.2 The methods outlined by these sources20,48-50 were used to isolate molecules 
from both the cell wall and cytosol of M. smegmatis during this assay. These isolated 
cell components were further separated using HPLC and the resulting isolates were 
analyzed using mass spectroscopy. The mass spectra were inspected for signals 
correlating to the previously described target compounds.  
 
Extraction of Bacterial Metabolites 
To begin the separation of cell culture components, aliquots (0.5 mL) of liquid 
culture media were removed and placed in sterile centrifuge tubes. The samples were 
centrifuged for 5 minutes at 13,300 rpm. The resulting supernatants were removed and 
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stored in additional sterile tubes at -20°C for future analysis. The remaining cell pellets 
were washed twice with sterile PBS (1 mL), discarding each supernatant formed, and 
then stored alongside the supernatant samples. This process was done at the 24, 32 
48, 72 and 96 hour time points.  
The method described by Sabareesh and Singh48 was adopted for extraction of 
the total lipid fraction of M. smegmatis. The previously collected cell pellets were thawed 
and a small stir bar was added to each tube along with 0.5 mL of CH2Cl2/methanol (2:1). 
The samples were allowed to stir while tightly capped for 24 hours, after which the stir 
bars were removed and the samples were centrifuged for 5 minutes to pellet any 
remaining solids. The organic solvents were carefully transferred into a clean uncapped 
tube then left to allow for evaporation. Once dried, the remaining lipid film was 
suspended in 1 mL of a 1:1 mixture of isopropanol and deionized water for further 
analysis. 
For extraction of metabolites in the supernatant fraction, the method described by 
Thomas et al.20 was utilized. Previously frozen samples were thawed and concentrated 
under vacuum to a volume of ~0.5 mL. Following concentration, each tube was charged 
with 0.5 mL of ethyl acetate and a small stir bar. The tubes were tightly capped and 
allowed to stir overnight. After 24 hours, the stir bars were removed and the organic 
layer was carefully removed and placed into a new plastic tube after the solvents had 
separated. The tubes were left uncapped until the ethyl acetate had evaporated, at 
which point the remaining solid was suspended 1 mL of isopropanol and deionized 
water (1:1) for further analysis. 
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HPLC Analysis of Bacterial Metabolites 
The supernatant fractions suspended in the 1:1 isopropanol-water were 
separated by reverse phase HPLC on a 250 mm C18 column with an inner diameter of 
4.6 mm. An isocratic flow of 50% 2-propanol (buffer A) and 50% water (buffer B) was 
run at 1.1 mL/min (effective rate = 1 mL/min) for 2 minutes. The sample was then 
injected and a 12-minute gradient to 80% buffer A was done at the same flow rate. The 
eluent composition was held for 24 minutes under the same flow rate, after which the 
gradient was brought back to 50% buffer A over 5 minutes. Lastly, an isocratic flow of 
50% buffer A was run at 1 mL/min for 5.5 minutes. A UV detector was employed for 
detection of analytes absorbing at 375 or 430 nm. These method conditions were used 
to analyze the previously extracted supernatants from the 96 H time point collection.  
To identify partially degraded cholesterol metabolites that retained the carbamate 
linked fluorophore, HPLC analysis was focused on the samples from cultures 
supplemented with compounds 2A and 2B. The chromatogram obtained for the 2A 
supernatant at 96 H revealed a peak that eluted at 28 minutes and absorbed at 375 nm 
(Figure 3.8). The retention time for this eluate was compared to that of the standard 
compound 2A under the same conditions, which was found to be 29 minutes. The 
slightly faster elution time seen for the supernatant sample may represent a more 
hydrophilic metabolite of 2A, such as the compound with a partially degraded 
cholesterol side chain (Figure 3.9). Mass spectral analysis of the collected HPLC 
fractions, as well as the unpurified samples, was started to determine if m/z values 
correlating to known cholesterol metabolites or hypothetical metabolites derived from 
compound 1-2 could be identified. 
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A 
 
 
B 
 
Figure 3.8. HPLC chromatograms of the putative metabolites derived from compound 
2A after 96 hours of bacterial incubation and of a 2A standard solution. A) Compound 
2A supernatant sample at 96 H. The observed analyte absorbed at 375 nm and had a 
retention time of 28 minutes. B) The standard of compound 2A eluted at 29 minutes and 
absorbed at 375 nm. Measured wavelengths: 430 nm (green), 375 nm (purple). 
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Figure 3.9. Hypothetical “AD-like” metabolite derived from compound 2A. 
 
Mass Spectral Analysis of Bacterial Metabolites  
Mass spectra of both the purified and unpurified supernatant samples were 
acquired on an ESI-QToF mass spectrometer and recorded over a 200-2000 m/z range 
in positive mode. Samples were diluted in isopropanol/water (1:1) and supplemented 
with a drop of 88% formic acid prior to analysis. The mass spectrometer settings used 
during data acquisition were identical for each sample tested (Table 3.1). 
 
Table 3.1. Mass spectrometer settings. 
 
Capillary Voltage 2600 V 
Sample Cone Voltage 145 V 
Extraction Cone Voltage 115 V 
Source Temperature 80°C 
Desolvation Temperature 130°C 
Flow Rate 10 µL/min 
Ion Mode Positive 
 
Mass spectral data obtained from the 96 H supernatants of cultures 
supplemented with either compound 2A or 2B were manually analyzed to eliminated 
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signals corresponding to residual Tyloxapol and related polyethylene glycol.51 Following 
the cancellation of these signals, the data were scanned for m/z values corresponding 
to the calculated adducts of unaltered compounds 2A and 2B (Appendix B).  
The data obtained from the unpurified supernatants of cholesterol, 2A and 2B at 
both 24 and 96 H showed m/z values corresponding to the known cholesterol 
metabolites AD and ADD (Figure 1.4 and Figures 3.10, 3.11, and 3.12). These findings 
suggest a mode of processing for the cholesterol portion of 2A and 2B that is similar to 
that observed for natural cholesterol. Presumably, hydrolytic removal of the carbamate-
linked naphthalimide would have to occur to form the α,β-unsaturated ketone present in 
AD, as well as the dienone found in ADD.  
 As described above, HPLC purification was performed to observe any changes 
in retention time of analytes that absorbed at 375 nm. The analyte that eluted at 28 
minutes was suspected to contain the speculated “AD-like” metabolite, which is shown 
in Figure 3.9. However, mass spectral analysis of the eluate lacked a signal with m/z 
value corresponding to 162A+H+ (Figure 3.13). The major component of this isolate 
appeared to have a molecular weight of 549 Da, which did not match any known 
cholesterol metabolites or hypothetical compounds derived from 2A. 
It should be noted that the results obtained from the HPLC and mass spectral 
experiments are preliminary and further investigation is needed to formulate more valid 
conclusions. Future studies will focus on more extensive metabolite identification and 
confirmation using MS/MS and HPLC. 
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Figure 3.10. Mass spectra of unpurified cholesterol supernatant at 24 (top) and 96 H 
(bottom). Peaks consistent with AD (calcd M+H+: m/z 287.2006 and M+Na+: 309.1825) 
and ADD (calcd M+H+: 285.1849 and M+Na+: 307.1669) are observed at 287.1465, 
309.1689, 285.1662, and 307.1565 for the 24 H sample and at 287.1742, 309.1825, 
285.1692, and 307.1697 for the 96 H sample.  
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Figure 3.11. Mass spectra of unpurified 2A supernatant at 24 (top) and 96 H (bottom). 
Peaks consistent with AD (calcd M+H+: m/z  287.2006 and M+Na+: 309.1825) and ADD 
(calcd M+H+: 285.1849 and M+Na+: 307.1669) are observed at 287.2039, 309.1944, 
285.1744, and 307.2073 for the 24 H sample and at 287.1742, 309.1910, 285.1774, and 
307.1782 for the 96 H sample. 
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Figure 3.12. Mass spectra of unpurified 2B supernatant at 24 (top) and 96 H (bottom). 
Peaks consistent with AD (calcd M+H+: m/z 287.2006 and M+Na+: 309.1825) and ADD 
(calcd M+H+: 285.1849 and M+Na+: 307.1669) are observed at 287.2285, 309.1944, 
285.1499, and 307.2158 for the 24 H sample and at 287.1825, 309.1825, 285.1499, and 
307.2158 for the 96 H sample. 
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Figure 3.13. Mass spectrum of analyte isolated from the 96 H 2A supernatant at 28 
minutes. No evidence for 162A (calcd M+H+: m/z 583.3167 and M+Na+: 605.2986) was 
found. Observed signals: m/z 522.5596, 538. 3696, 550.5834, 578.6290. 
 
 
 
3.6 Discussion of Assay Results 
 The robust and similar growth observed for all cultures tested in the Tween-80 
assay suggests that the supplemented detergent was the preferred carbon source 
compared to compounds 1-2. This preference would account for the absence of 
decreased growth seen in the 1A and 1B cultures for the Tyloxapol assay. The 
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utilization of Tween-80 may have also prevented M. smegmatis from transitioning into a 
metabolic state20 in which cholesterol processing genes are up-regulated. In the 
absence of such increased gene expression, it’s likely that compounds 2A and 2B were 
not taken up and degraded in amounts that would have had a significant effect on the 
phenotype observed.  
 Once the Tween-80 had been replaced, the growth patterns observed were 
noticeably different. First, the free fluorophores tested (1A and 1B) showed an inhibitory 
effect compared to the other conditions tested (Figure 3.14). This could be a 
consequence of toxicity by the unaltered compounds or by derived metabolites. 
However, the data obtained from mass spectroscopy studies suggests that the intact 
fluorophores are likely the cause, as m/z ratios corresponding to their protonated 
masses were seen as dominate signals. This observation is in line with other reports of 
naphthalimides possessing anti-bacterial properties, whether through DNA 
intercalation33 or some other mechanism. 
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Figure 3.14. Growth of M. smegmatis in defined minimal medium supplemented 
with compounds 1-2 and Tyloxapol.  
 
 
The cholesterol conjugates 2A and 2B showed an increase in viable cell counts 
compared to the control and cholesterol cultures. This increase could be caused by the 
ability of the bacteria to utilize both the cholesterol and naphthalimide portions of 
compounds 2A and 2B as carbon sources. However, if the naphthalimide portion is 
consumed, it is likely processed differently than the free fluorophores 1A and 1B since 
there is no delayed detrimental effect observed within the time period used in this 
assay. The mass spectral data is in accord with this idea, as there were no significant 
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signals observed that match to the calculated masses of 1A and 1B in the cholesterol 
conjugate samples. 
 While the underlying mechanism of breakdown remains undetermined, the 
evidence of utilization of modified cholesterol is compelling. The indication of compound 
2A and 2B uptake by M. smegmatis is particularly intriguing as previous knockout 
studies17-19 have shown the mce4 cholesterol transport system to be an important 
virulence factor for M. tuberculosis. The work done by Mohn et al.17 demonstrated 
multiple substrates for this transporter, which showed selectivity for steroids that contain 
a long, hydrophobic side chain attached to the D ring, such as that found in cholesterol. 
If binding and recognition of the side chain is indeed the key factor in determining 
whether compounds are imported, then it is possible that 2A and 2B could be 
substrates for this system, as their luminescent tag units are located far away from the 
hydrophobic tail found on cholesterol (Figure 3.15). Additionally, the compounds may 
be imported though another transport system,17,18 which may explain the increased 
growth observed compared to cholesterol.  
 
 
Figure 3.15. Compound 2A. 
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Many important questions remained unanswered with regards to the role of lipid 
metabolism in Mycobacterium virulence. However, this study suggests that it is possible 
for specifically modified cholesterol analogues to enter the cell, likely through an active 
transport pathway. This finding is important as it indicates cholesterol could be used as 
a “Trojan horse” for future anti-mycobacterial drugs. It is well known that the thick and 
waxy cell wall that characterizes Mycobacterium species plays a significant role during 
infection, protecting the organism from our body’s defenses. Its presence also 
decreases the efficacy of traditional antibiotics, the polarity of which slows their diffusion 
through the tightly packed, lipophilic barrier. If this barrier could be overcome by 
exploiting of a known pathway used by the bacteria during infection, it could provide a 
new way to deliver both existing and new anti-mycobacterial drugs.  
 
 
 
 
 
 
 
 
 
	   
4. EXPERIMENTAL 
 
 
 
4.1 Chemical Experimental Section 
 
 
 
2-Butyl-6-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione (1.1) 
 
 Compound 1.1 was synthesized using a modified version of the procedure 
described by Triboni et al.34 N-Butylamine was used in 6.75-fold excess, as opposed to 
the 10-fold excess stated in the referenced paper, and the dilute HCl wash preceding 
filtration was omitted. The adopted method produced average yields of 96%. Spectral 
data were in accordance with the literature. 1H NMR (CDCl3) δ 1.01 (t, 3H), 1.47 (m, 
2H), 1.75 (m, 2H), 4.22 (t, 2H), 8.01 (t, 1H), 8.44 (d, 1H), 8.72 (d, 1H), 8.75 (d, 1H), 8.78 
(d, 1H). HRMS (ESI) calcd for C16H14N2O4 (M + H)+ 299.1032, found 299.1107. 
 
2-(3-Methoxypropyl)-6-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione (1.2) 
 Compound 1.2 was synthesized using the procedure described for compound 
1.1, replacing N-butylamine with an equivalent amount of 3-methoxypropylamine. 
(71%). Mp 178-179 °C. 
 
6-Amino-2-butyl-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione (1A) 
 Previous work36 has shown that 4-nitro-1,8-naphthalic anhydride is readily 
reduced to the corresponding amine with the use of a hydrogenation apparatus  and 
catalytic amounts of Pd/C. Compound 1.1 was reduced in a similar fashion by placing 
10% palladium on carbon catalyst (0.028 g) into a Pyrex bottle followed immediately by 
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150 mL of 95% ethanol. Nitro compound 1.1 (0.34 g, 1.1 mmol) was then introduced 
into the ethanol solution. The bottle was placed on the hydrogenator and agitated for 90 
minutes under 34 psi of H2. When complete, the dark green solution was filtered 
through fluted filter paper into a tared round-bottom flask. The ethanol was then 
removed under vacuum. The weight of dried compound 1A was 0.29 g (1.1 mmol), 
giving a percent yield of 94%. Mp 74-88°C; 1H NMR (CDCl3) δ 1.00 (t, 3H), 1.47 (m, 
2H), 1.73 (m, 2H), 4.19 (t, 2H), 4.94 (b rs, 2H), 6.92 (d, 1H), 7.69 (t, 1H), 8.12 (d, 1H), 
8.44 (d, 1H), 8.64 (d, 1H); HRMS (ESI) calcd for C16H16N2O2 (M + H)+ 269.1290, found 
269.1225; calcd for C16H16N2O2 (M + Na)+ 291.1109, found 291.1001; calcd for 
C16H16N2O2 (M + K)+ 307.0849, found 307.1198; calcd for C16H16N2O2 (2M + Na)+ 
559.2321, found 559.2518. 
 
6-Amino-2-(3-methoxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1B) 
 Compound 1B was subjected to the same reduction process utilized for 
compound 1A. The yield was 87%. Mp 108-114°C; 1H NMR (CDCl3) δ 2.04 (m, 2H), 
3.3589 (s, 3H), 3.54 (t, 2H), 4.28 (t, 2H), 4.96 (b rs, 2H), 6.92 (d, 1H), 7.68 (t, 1H), 8.14 
(d, 1H), 8.44 (d, 1H), 8.64 (d, 1H); HRMS (ESI) calcd for C16H16N2O3 (M + H)+ 285.1239, 
found 285.1143; calcd for C16H16N2O3 (M + Na)+ 307.1059, found 307.1028; calcd for 
C16H16N2O3 (M + K)+ 323.0798, found 323.0895; calcd for C16H16N2O3 (2M + Na)+ 
591.2220, found 591.2524. 
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10,13-Dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-butyl-1,3-dioxo-2,3-dihydro-
1H-benzo[de]isoquinolin-6-ylcarbamate (2A) 
 Fluorophore 1A (0.095 g, 0.35 mmol) was suspended in 10 mL of stirring ethyl 
acetate under nitrogen. The mixture was then heated to 45°C using a preheated oil 
bath. An equivalent amount of N,N-diisopropylethylamine (0.045 g, 0.35 mmol) was 
added to the burnt orange solution in one portion. After 5 minutes, no color change was 
observed.  Cholesteryl chloroformate (0.158 g, 0.35 mmol) was introduced, and the 
reaction was monitored by TLC (9:1 CH2Cl2-ethyl acetate). TLC analysis showed spots 
correlating to compound 1A and a faster blue spot not found in the starting 
naphthalimide. After 10 days, the reaction was allowed to cool and the volatiles were 
removed under vacuum. The solid residue was purified by flash chromatography using 
hexanes/dichloromethane (1:1), to remove any excess cholesterol chloroformate and 
other cholesterol-like impurities, followed by CH2Cl2-ethyl acetate (9:1). Solvents were 
removed under vacuum and compound 2A was isolated as a tacky green-yellow solid 
(0.140 g, crude yield of 58%). Analytically pure samples were obtained by trituration 
with warm 2-propanol. Mp 61-75 °C; 1H NMR (CDCl3) δ 0.70 (s, 6H), 0.87-2.01 (m, 
36H), 2.41 (m, 6H), 4.19 (t, 2H), 4.56 (m, 1H), 5.39 (d, 2H), 5.72 (d, 1H), 7.53 (s, 1H), 
7.78 (t, 1H), 8.23 (d, 1H), 8.39 (d, 1H), 8.60 (d, 1H), 8.66 (d, 1H); 13C NMR (CDCl3) δ 
11.86, 13.85, 18.72, 19.40, 20.40, 21.06, 22.56, 22.82, 23.84, 28.01, 28.24, 28.38, 
29.70, 30.22, 31.89, 31.92, 35.80, 36.19, 36.60, 37.07, 38.75, 38.77, 39.19, 39.52, 
39.75, 42.32, 50.02, 56.14, 56.70, 74.12, 74.23, 116.53, 117.63, 120.66, 122.26, 
123.16, 123.16, 123.49, 124.50, 125.98, 126.48, 126.53, 128.96, 131.19, 132.59, 
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139.27, 140.06, 145.30, 145.60, 152.71, 155.42, 155.58, 163.71, 164.20, 164.58. 
HRMS (ESI) calcd for C44H60N2O4 (M + H)+ 681.4631, found 681.4152. 
 
10,13-Dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-(3-methoxypropyl)-1,3-dioxo-
2,3-dihydro-1H-benzo[de]isoquinolin-6-ylcarbamate (2B) 
 Compound 2B was synthesized from compound 1B using the same protocol 
reported for compound 2A. During purification, a solvent system consisting of 10:1 
CH2Cl2-ethyl acetate was used following the 1:1 hexanes-CH2Cl2 wash. (81%) Mp 41-
130 °C; 1H NMR (CDCl3) δ 0.71 (s, 6H), 0.90-1.56 (m, 20H), 1.86 (m, 5H), 2.05 (m, 6H), 
2.30 (m, 4H), 2.51 (m, 2H), 3.36 (s, 3H), 3.55 (t, 2H), 4.30 (t, 2H), 4.73 (m, 1H), 5.39 (d, 
2H), 5.46 (d, 1H), 7.53 (s, 1H), 7.80 (t, 1H), 8.22 (d, 1H), 8.44 (d, 1H), 8.62 (d, 1H), 8.66 
(d, 1H); 13C NMR (CDCl3) δ 11.87, 18.73, 19.41, 21.09, 22.57, 22.83, 23.84, 24.30, 
28.02, 28.24, 31.64, 31.91, 35.80, 36.20, 36.59, 36.94, 37.26, 37.87, 38.37, 39.52, 
39.79, 42.33, 50.01, 50.13, 56.16, 56.69, 56.77, 58.50, 70.65, 71.82, 116.47, 117.52, 
121.72, 122.79, 123.18, 123.40, 126.00, 126.49, 128.95, 131.23, 132.63, 139.25, 
139.30, 140.76, 152.70, 163.69, 164.18. HRMS (ESI) calcd for C44H60N2O5 (M + H)+ 
697.9810, found 697.9772.  
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4.2 Biological Experimental Section 
 
 
Bacterial Strain and Media. M. smegmatis mc2 155 was grown on LB agar to obtain 
isolated colonies for subsequent assays.  
For Tween-80 assays, both LB and modified M9 media were used. To prepare 
the modified M9 media, Na2HPO4 (6 g/L), KH2PO4 (3 g/L), NaCl (0.5 g/L), NH4Cl (1 g/L), 
casamino acids (2.5 g/L) were dissolved in deionized water and the pH was adjusted to 
7.4 before autoclaving. Once the sterile solution was cooled, 1 M MgSO4 (2 mL), 1 M 
CaCl2 (0.1 mL), 20% glucose (0.5 mL), and 5 mM ferric citrate (100 µL) was added and 
the medium was filtered sterilized.  
For Tyloxapol assays, bacteria were first grown in modified 7H9 broth containing 
(NH4)2SO4 (0.50 g/L), Na2HPO4 (2.5 g/L), KH2PO4 (1 g/L), NaCl (0.10 g/L), MgSO4 (0.05 
g/L), CaCl2 (0.0005 g/L), ZnSO4 (0.001 g/L), CuSO4 (0.001 g/L), L-glutamic acid (0.50 
g/L), and 5 mM ferric citrate (100 µL/L) dissolved in 1 L of distilled deionized water. This 
solution was supplemented 5 mL 10% Tween-80 and 100 mL albumin-dextrose-saline 
(ADS) solution. To prepare the 10% Tween-80 solution, 20 g (18.87 mL) of Tween-80 
was diluted into distilled deionized water equaling a final volume of 200 mL. The Tween-
80 mixture was stirred on low heat (~65°C) for about 15 minutes to completely dissolve 
the detergent. The prepared solution was then stored in a closed cabinet as Tween-80 
is light sensitive. To make the ADS solution, NaCl (8.1 g/L), Bovine Serum Albumin 
Fraction V (50 g/L), anhydrous dextrose (20 g/L) was dissolved in distilled deionized 
water and later sterilized using a 0.22 µm filter. To monitor growth on defined carbon 
sources, a minimal medium utilized by Pandey and Sassetti47 was used. The medium, 
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which was slightly modified from the reference article, was prepared by dissolving 
asparagine (0.5 g/L), KH2PO4 (1 g/L), Na2HPO4 (2.5 g/L), MgSO4 (0.22 g/L), CaCl2 
(0.0005 g/L), ZnSO4 (0.0001 g/L) and 5 mM ferric citrate (100 µL/L) into distilled 
deionized water and then sterilizing the solution using a 0.22 µm filter.  
 
Fluorophore Solutions. The 2.5 mM fluorophore emulsions used in the Tween-80 
assays were prepared by suspending each powdered compound (0.0125 mmol) in 5 mL 
of Tween-80. Once suspended, the emulsion was vortexed to equally distribute the 
compound throughout the detergent.  
To make the 1.15 mM fluorophore solutions used in the Tyloxapol assays, each 
compound (Butyl Fluorophore (7.73 mg), Butyl Blue (19.61 mg), Methoxy Fluorophore 
(8.19 mg), Methoxy Blue (20.07 mg), and Cholesterol (11.14 mg)) was suspended in 
192 µL of 95% ethanol and 96 µL of Tyloxapol in a sterile eppendorf tube. To better 
solubilize the powdered compounds, the tubes were heated in a water bath (55°C) for 5-
10 minutes and then vortexed to evenly distribute the compound in the ethanol-
Tyloxapol mixture.  
 
Disk Diffusion Assay. LB Agar plates were prepared and an isolated colony of M. 
smegmatis was suspended in sterile PBS solution. LB agar plates were inoculated with 
the bacterial solution. A sterile paper disk was placed in the center of each inoculated 
plate and then test compounds were introduced onto the disks as solutions in DMSO 
(10 µL; stock concentration = 7.31x10-3 M). Plates were incubated for 3 days and then 
evaluated for bacterial sensitivity.  
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Growth of M. smegmatis in the Presence of Compounds 1-2 and Tween-80 
supplementation. M. smegmatis mc2 155 was streaked onto an LB plate to obtain an 
isolated colony for the growth assay. After incubating for two days, a colony was 
collected and suspended into 1.5 mL of sterile PBS. An OD600 measurement was 
acquired and the solution was adjusted to inoculate the broth with 1x10-3 CFU/mL. A 
series of 125 mL Erlenmeyer flask containing 24.5 mL of LB medium was autoclaved 
along with an equal amount of empty 125 mL Erlenmeyer flask that would later house 
the M9 cultures. Once cooled, 24.5 mL of M9 medium was added to each empty flask. 
Each flask then received 500 µL of a Tween-fluorophore emulsion (concentration = 2.5 
mM) and was inoculated with the prepared M. smegmatis solution. Once the solutions 
were uniform, each culture was subjected to a series of serial dilutions and plated to 
obtain an initial CFU count. The flasks were placed in a shaker at 37°C and growth was 
monitored by plating 10-fold serial dilutions. The dilution and plating series was 
conducted at 8-hour intervals until 48 hours had passed, then every 24 hours thereafter. 
To obtain the CFU/mL of each culture, the bacterial solutions were serial diluted using 
sterile PBS and subsequently plated on LB agar plates. Colonies were counted two 
days after being plated. Removal of the media for analysis did not cause the volume of 
the culture to drop below half of the initial volume.   
 
Growth of M. smegmatis in the Presence of Compounds 1-2 and Tyloxapol 
Supplementation. For growth assessment of M. smegmatis on defined media, Tween-
80 was substituted with Tyloxapol, a detergent that has been shown to not have an 
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inhibitory or beneficial effect on cell growth.47 The LB and M9 media was replaced with 
a defined minimal media used by Pandey and Sassetti.47 An isolated colony of bacteria 
was collected from an LB agar plate and suspended in 75 µL of sterile 7H9 media. To 
prepare the initial culture, 250 mL of sterile 7H9 medium was added to a 500 mL 
Erlynmeyer flask and then inoculated with 25 µL of the previously prepared bacterial 
suspension. Bacterial growth was monitored using OD600 measurements.  
Once mid-exponential phase had been reached (OD600 ≈ 0.5), the 7H9 culture was 
divided into 8 sterilized centrifuged tubes, each tube receiving 25.0 mL of culture. The 
tubes were centrifuged for 15 minutes at 10K rpm. The supernatant was removed and 
the bacterial pellet was washed with sterile PBS then centrifuged under the previous 
conditions. The supernatant was again removed and the wash procedure was repeated. 
The remaining pellet was suspended in 25 mL of defined minimal media by quickly 
vortexing the culture. A fluorophore solution was then added to each tube and vortexed 
to evenly distribute both the compound and the bacteria. The 25 mL culture within each 
centrifuge tube was then divided into 4 mL aliquots among 6 culture tubes, for future 
CFU counts and metabolite identification studies. A 200 µL aliquot was removed from 
each “CFU tube,” serial diluted and then plated on LB agar to obtain a starting bacterial 
count. This process was repeated every 24 hours for each compound culture tube until 
one week had passed.  
 
Extraction of Cholesterol- and Fluorophore-derived Bacterial Metabolites. To 
isolate known cholesterol metabolites and to analyze any possible metabolites from 
compounds 1-4, culture samples were collected from each tube in 0.5 mL aliquots and 
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placed in sterile centrifuge tubes. The samples were centrifuged for 5 minutes at 13,300 
rpm. The supernatants were collected and stored in sterile tubes at -20°C for future 
analysis. The remaining cell pellets were washed twice with 1 mL portions of sterile PBS 
and the resulting supernatants were discarded. The washed pellets were stored with the 
previously obtained supernatant samples at -20°C.  
The method described by Sabareesh and Singh48 was adopted for extraction of 
the total lipid fraction of M. smegmatis. The previously collected cell pellets were thawed 
and a small stir bar was added to each tube along with 0.5 mL of CH2Cl2/methanol (2:1). 
The samples were allowed to stir while tightly capped for 24 hours, after which the stir 
bars were removed and the samples were centrifuged for 5 minutes to pellet any 
remaining solids. The organic solvents were carefully transferred into a clean uncapped 
tube then left to allow for evaporation. Once dried, the remaining lipid film was 
suspended in 1 mL of a 1:1 mixture of isopropanol and deionized water for further 
analysis. 
For extraction of metabolites in the supernatant fraction, the method described by 
Thomas et al.20 was utilized. Previously frozen samples were thawed and concentrated 
under vacuum to a volume of ~0.5 mL. Following concentration, each tube was charged 
with 0.5 mL of ethyl acetate and a small stir bar. The tubes were tightly capped and 
allowed to stir overnight. After 24 hours, the stir bars were removed and the organic 
layer was carefully removed and placed into a new plastic tube after the solvents had 
separated. The tubes were left uncapped until the ethyl acetate had evaporated, at 
which point the remaining solid was suspended 1 mL of isopropanol and deionized 
water (1:1) for further analysis. 
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HPLC and Mass Spectral Analysis of Metabolites Derived from Compounds 1-2. 
The total lipid fractions suspended in the 1:1 isopropanol-water were separated by 
reverse phase HPLC on a 250 mm C18 column with an inner diameter of 4.6 mm. An 
isocratic flow of 50% 2-propanol (buffer A) and 50% water (buffer B) was run at 1.1 
mL/min (effective rate = 1 mL/min) for 2 minutes. The sample was then injected and a 
12-minute gradient to 80% buffer A was done at the same flow rate. The gradient was 
held for 24 minutes under the same flow rate, after which the gradient was brought back 
to 50% buffer A over 5 minutes. Lastly, an isocratic flow of 50% buffer A was run at 1 
mL/min for 5.5 minutes. A UV detector was employed for detection of analytes 
absorbing at 375 or 430 nm.  
Mass spectra were acquired on an ESI-QToF mass spectrometer and recorded 
over a 200-2000 m/z range in positive mode. Samples were diluted in isopropanol/water 
(1:1) and supplemented with a drop of 88% formic acid prior to analysis. The settings 
listed in Table 4.1 were used during data acquisition for each sample tested. 
 
Table 4.1. Mass spectrometer settings. 
Capillary Voltage 2600 V 
Sample Cone Voltage 145 V 
Extraction Cone Voltage 115 V 
Source Temperature 80°C 
Desolvation Temperature 130°C 
Flow Rate 10 µL/min 
Ion Mode Positive 
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APPENDIX A: Database of Cholesterol Metabolites 
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437.3026 
1200.4229 
1198.4073 
1216.4178 
1214.4022 
1158.3760 
1156.3603 
M
+K
 
425.3180 
423.3024 
439.2973 437.2816 
453.2766 
1216.3968 
1214.3812 
1232.3918 
1230.3761 
1174.3499 
1172.3342 
2M
+H
 
773.7170 
769.6857 
801.6755 797.6442 
829.6341 
2355.8747 
2351.8434 
2387.8645 
2383.8332 
2271.7808 
2267.7495 
2M
+N
a 
795.6990 
791.6677 
823.6575 819.6262 
851.6160 
2377.8566 
2373.8253 
2409.8464 
2405.8151 
2293.7627 
2289.7314 
2M
+K
 
811.6729 
807.6416 
839.6314 835.6001 
867.5899 
2393.8305 
2389.7992 
2425.8204 
2421.7891 
2309.7366 
2305.7053 
 C
om
pound 
12 
13 
14 
15 
A
D
 
A
D
D
 
9-O
H
A
D
 
9-O
H
A
D
D
 
3-H
.S
.A
. 
21 
22 
D
O
H
N
A
A
 
E
xact M
ass 
1151.3817 1149.3660 1107.3554 1105.3398 286.1933 284.1776 302.1882 
300.1725 
300.1725 316.1675 348.1573 238.1205 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
+2H
 
577.7054 
576.6976 
555.6923 
554.6844 
145.1112 144.1034 153.1086 
152.1008 
152.1008 160.0983 176.0932 121.0748 
M
+H
+N
a 
599.6873 
598.6795 
577.6742 
576.6664 
167.0931 166.0853 175.0906 
174.0828 
174.0828 182.0802 198.0751 143.0567 
M
+H
+K
 
615.6613 
614.6534 
593.6482 
592.6403 
183.0671 182.0592 191.0645 
190.0567 
190.0567 198.0542 214.0491 159.0307 
M
+H
 
1152.3889 1150.3733 1108.3627 1106.3471 287.2006 285.1849 303.1955 
301.1798 
301.1798 317.1747 349.1646 239.1278 
M
+N
a 
1174.3709 1172.3552 1130.3447 1128.3290 309.1825 307.1668 325.1774 
323.1618 
323.1618 339.1567 371.1465 261.1097 
M
+K
 
1190.3448 1188.3292 1146.3186 1144.3029 325.1564 323.1408 341.1514 
339.1357 
339.1357 355.1306 387.1204 277.0837 
2M
+H
 
2303.7706 2299.7393 2215.7182 2211.6869 573.3938 569.3625 605.3837 
601.3524 
601.3524 633.3422 697.3219 477.2483 
2M
+N
a 
2325.7525 2321.7212 2237.7001 2233.6688 595.3758 591.3445 627.3656 
623.3343 
623.3343 655.3241 719.3038 499.2302 
2M
+K
 
2341.7265 2337.6952 2253.6740 2249.6427 611.3497 607.3184 643.3395 
639.3082 
639.3082 671.2981 735.2777 515.2042 
       
81 	  
	   	  
C
om
pound 
2A
  
3 
4 
5 
6 
7 
8 
E
xact M
ass 
680.4553 
696.4502 
694.4346 
710.4295 
1455.505 
1453.4894 
1471.4999 
 
 
 
 
 
 
 
 
M
+2H
 
342.2422 
350.2397 
349.2319 
357.2293 
729.7671 
728.7593 
737.7645 
M
+H
+N
a 
364.2241 
372.2216 
371.2138 
379.2112 
751.7490 
750.7412 
759.7464 
M
+H
+K
 
380.1981 
388.1955 
387.1877 
395.1852 
767.7229 
766.7151 
775.7204 
M
+H
 
681.4626 
697.4575 
695.4419 
711.4368 
1456.5123 
1454.4967 
1472.5072 
M
+N
a 
703.4445 
719.4394 
717.4238 
733.4187 
1478.4942 
1476.4786 
1494.4891 
M
+K
 
719.4185 
735.4134 
733.3978 
749.3927 
1494.4682 
1492.4526 
1510.4631 
2M
+H
 
1361.9179 
1393.9077 
1389.8765 
1421.8663 
2912.0173 
2907.9861 
2944.0071 
2M
+N
a 
1383.8998 
1415.8896 
1411.8584 
1443.8482 
2933.9992 
2929.9680 
2965.9890 
2M
+K
 
1399.8738 
1431.8636 
1427.8324 
1459.8222 
2949.9732 
2945.9420 
2981.9630 
 
9 
10 
11 
12 
13 
14 
15 
16 
1469.4843 
1413.4581 
1411.4424 
1429.453 
1427.4373 
1385.4269 
1383.4111 
582.3094 
 
 
 
 
 
 
 
 
736.7567 
708.7436 
707.7358 
716.7411 
715.7332 
694.7280 
693.7201 
293.1693 
758.7386 
730.7255 
729.7177 
738.7230 
737.7151 
716.7099 
715.7020 
315.1512 
774.7126 
746.6995 
745.6916 
754.6969 
753.6891 
732.6839 
731.6760 
331.1251 
1470.4916 
1414.4654 
1412.4497 
1430.4603 
1428.4446 
1386.4342 
1384.4184 
583.3167 
1492.4735 
1436.4473 
1434.4316 
1452.4422 
1450.4265 
1408.4161 
1406.4003 
605.2986 
1508.4475 
1452.4213 
1450.4056 
1468.4162 
1466.4005 
1424.3901 
1422.3743 
621.2726 
2939.9759 
2827.9235 
2823.8921 
2859.9133 
2855.8819 
2771.8611 
2767.8295 
1165.6261 
2961.9578 
2849.9054 
2845.8740 
2881.8952 
2877.8638 
2793.8430 
2789.8114 
1187.6080 
2977.9318 
2865.8794 
2861.8480 
2897.8692 
2893.8378 
2809.8170 
2805.7854 
1203.5820 
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C
om
pound 
2B
 
3 
4 
5 
6 
7 
8 
E
xact M
ass 
696.4502 
712.4451 
710.4295 
726.4244 
1471.4999 
1469.4843 
1487.4948 
 
 
 
 
 
 
 
 
M
+2H
 
350.2397 
358.2371 
357.2293 
365.2268 
737.7645 
736.7567 
745.7620 
M
+H
+N
a 
372.2216 
380.2190 
379.2112 
387.2087 
759.7464 
758.7386 
767.7439 
M
+H
+K
 
388.1955 
396.1930 
395.1852 
403.1826 
775.7204 
774.7126 
783.7178 
M
+H
 
697.4575 
713.4524 
711.4368 
727.4317 
1472.5072 
1470.4916 
1488.5021 
M
+N
a 
719.4394 
735.4343 
733.4187 
749.4136 
1494.4891 
1492.4735 
1510.4840 
M
+K
 
735.4134 
751.4083 
749.3927 
765.3876 
1510.4631 
1508.4475 
1526.4580 
2M
+H
 
1393.9077 
1425.8975 
1421.8663 
1453.8561 
2944.0071 
2939.9759 
2975.9969 
2M
+N
a 
1415.8896 
1447.8794 
1443.8482 
1475.8380 
2965.9890 
2961.9578 
2997.9788 
2M
+K
 
1431.8636 
1463.8534 
1459.8222 
1491.8120 
2981.9630 
2977.9318 
3013.9528 
 
9 
10 
11 
12 
13 
14 
15 
16 
1485.4792 
1429.453 
1427.4373 
1445.4479 
1443.4322 
1401.4218 
1399.406 
598.3043 
 
 
 
 
 
 
 
 
744.7542 
716.7411 
715.7332 
724.7385 
723.7307 
702.7255 
701.7176 
301.1667 
766.7361 
738.7230 
737.7151 
746.7204 
745.7126 
724.7074 
723.6995 
323.1486 
782.7100 
754.6969 
753.6891 
762.6944 
761.6865 
740.6813 
739.6734 
339.1226 
1486.4865 
1430.4603 
1428.4446 
1446.4552 
1444.4395 
1402.4291 
1400.4133 
599.3116 
1508.4684 
1452.4422 
1450.4265 
1468.4371 
1466.4214 
1424.4110 
1422.3952 
621.2935 
1524.4424 
1468.4162 
1466.4005 
1484.4111 
1482.3954 
1440.3850 
1438.3692 
637.2675 
2971.9657 
2859.9133 
2855.8819 
2891.9031 
2887.8717 
2803.8509 
2799.8193 
1197.6159 
2993.9476 
2881.8952 
2877.8638 
2913.8850 
2909.8536 
2825.8328 
2821.8012 
1219.5978 
3009.9216 
2897.8692 
2893.8378 
2929.8590 
2925.8276 
2841.8068 
2837.7752 
1235.5718 
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